These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 20603615)

  • 1. An anti-Axl monoclonal antibody attenuates xenograft tumor growth and enhances the effect of multiple anticancer therapies.
    Ye X; Li Y; Stawicki S; Couto S; Eastham-Anderson J; Kallop D; Weimer R; Wu Y; Pei L
    Oncogene; 2010 Sep; 29(38):5254-64. PubMed ID: 20603615
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel human anti-AXL monoclonal antibody attenuates tumour cell migration.
    Duan Y; Luo L; Qiao C; Li X; Wang J; Liu H; Zhou T; Shen B; Lv M; Feng J
    Scand J Immunol; 2019 Aug; 90(2):e12777. PubMed ID: 31075180
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Axl as a potential therapeutic target in cancer: role of Axl in tumor growth, metastasis and angiogenesis.
    Li Y; Ye X; Tan C; Hongo JA; Zha J; Liu J; Kallop D; Ludlam MJ; Pei L
    Oncogene; 2009 Oct; 28(39):3442-55. PubMed ID: 19633687
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic Activity of Anti-AXL Antibody against Triple-Negative Breast Cancer Patient-Derived Xenografts and Metastasis.
    Leconet W; Chentouf M; du Manoir S; Chevalier C; Sirvent A; Aït-Arsa I; Busson M; Jarlier M; Radosevic-Robin N; Theillet C; Chalbos D; Pasquet JM; Pèlegrin A; Larbouret C; Robert B
    Clin Cancer Res; 2017 Jun; 23(11):2806-2816. PubMed ID: 27923843
    [No Abstract]   [Full Text] [Related]  

  • 5. Gas6 derived from cancer-associated fibroblasts promotes migration of Axl-expressing lung cancer cells during chemotherapy.
    Kanzaki R; Naito H; Kise K; Takara K; Eino D; Minami M; Shintani Y; Funaki S; Kawamura T; Kimura T; Okumura M; Takakura N
    Sci Rep; 2017 Sep; 7(1):10613. PubMed ID: 28878389
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, synthesis, and validation of Axl-targeted monoclonal antibody probe for microPET imaging in human lung cancer xenograft.
    Liu S; Li D; Guo J; Canale N; Li X; Liu R; Krasnoperov V; Gill PS; Conti PS; Shan H; Li Z
    Mol Pharm; 2014 Nov; 11(11):3974-9. PubMed ID: 24978094
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical validation of AXL receptor as a target for antibody-based pancreatic cancer immunotherapy.
    Leconet W; Larbouret C; Chardès T; Thomas G; Neiveyans M; Busson M; Jarlier M; Radosevic-Robin N; Pugnière M; Bernex F; Penault-Llorca F; Pasquet JM; Pèlegrin A; Robert B
    Oncogene; 2014 Nov; 33(47):5405-14. PubMed ID: 24240689
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction, regulation, and biologic function of Axl receptor tyrosine kinase in Kaposi sarcoma.
    Liu R; Gong M; Li X; Zhou Y; Gao W; Tulpule A; Chaudhary PM; Jung J; Gill PS
    Blood; 2010 Jul; 116(2):297-305. PubMed ID: 20442363
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of the phenylpyrazolo[3,4-
    Lee HJ; Pham PC; Pei H; Lim B; Hyun SY; Baek B; Kim B; Kim Y; Kim MH; Kang NW; Min HY; Kim DD; Lee J; Lee HY
    Theranostics; 2021; 11(4):1918-1936. PubMed ID: 33408789
    [No Abstract]   [Full Text] [Related]  

  • 10. Enapotamab vedotin, an AXL-specific antibody-drug conjugate, shows preclinical antitumor activity in non-small cell lung cancer.
    Koopman LA; Terp MG; Zom GG; Janmaat ML; Jacobsen K; Gresnigt-van den Heuvel E; Brandhorst M; Forssmann U; de Bree F; Pencheva N; Lingnau A; Zipeto MA; Parren PW; Breij EC; Ditzel HJ
    JCI Insight; 2019 Nov; 4(21):. PubMed ID: 31600169
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mer or Axl receptor tyrosine kinase inhibition promotes apoptosis, blocks growth and enhances chemosensitivity of human non-small cell lung cancer.
    Linger RM; Cohen RA; Cummings CT; Sather S; Migdall-Wilson J; Middleton DH; Lu X; Barón AE; Franklin WA; Merrick DT; Jedlicka P; DeRyckere D; Heasley LE; Graham DK
    Oncogene; 2013 Jul; 32(29):3420-31. PubMed ID: 22890323
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Paradoxical role of the proto-oncogene Axl and Mer receptor tyrosine kinases in colon cancer.
    Bosurgi L; Bernink JH; Delgado Cuevas V; Gagliani N; Joannas L; Schmid ET; Booth CJ; Ghosh S; Rothlin CV
    Proc Natl Acad Sci U S A; 2013 Aug; 110(32):13091-6. PubMed ID: 23878224
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor tissue and plasma levels of AXL and GAS6 before and after tyrosine kinase inhibitor treatment in EGFR-mutated non-small cell lung cancer.
    Nonagase Y; Takeda M; Azuma K; Hayashi H; Haratani K; Tanaka K; Yonesaka K; Ishii H; Hoshino T; Nakagawa K
    Thorac Cancer; 2019 Oct; 10(10):1928-1935. PubMed ID: 31419057
    [TBL] [Abstract][Full Text] [Related]  

  • 14. R428, a selective small molecule inhibitor of Axl kinase, blocks tumor spread and prolongs survival in models of metastatic breast cancer.
    Holland SJ; Pan A; Franci C; Hu Y; Chang B; Li W; Duan M; Torneros A; Yu J; Heckrodt TJ; Zhang J; Ding P; Apatira A; Chua J; Brandt R; Pine P; Goff D; Singh R; Payan DG; Hitoshi Y
    Cancer Res; 2010 Feb; 70(4):1544-54. PubMed ID: 20145120
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mistletoe (Viscum album) extract targets Axl to suppress cell proliferation and overcome cisplatin- and erlotinib-resistance in non-small cell lung cancer cells.
    Kim S; Kim KC; Lee C
    Phytomedicine; 2017 Dec; 36():183-193. PubMed ID: 29157814
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Warfarin Blocks Gas6-Mediated Axl Activation Required for Pancreatic Cancer Epithelial Plasticity and Metastasis.
    Kirane A; Ludwig KF; Sorrelle N; Haaland G; Sandal T; Ranaweera R; Toombs JE; Wang M; Dineen SP; Micklem D; Dellinger MT; Lorens JB; Brekken RA
    Cancer Res; 2015 Sep; 75(18):3699-705. PubMed ID: 26206560
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Small molecule inhibitors block Gas6-inducible TAM activation and tumorigenicity.
    Kimani SG; Kumar S; Bansal N; Singh K; Kholodovych V; Comollo T; Peng Y; Kotenko SV; Sarafianos SG; Bertino JR; Welsh WJ; Birge RB
    Sci Rep; 2017 Mar; 7():43908. PubMed ID: 28272423
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting Axl favors an antitumorigenic microenvironment that enhances immunotherapy responses by decreasing Hif-1α levels.
    Goyette MA; Elkholi IE; Apcher C; Kuasne H; Rothlin CV; Muller WJ; Richard DE; Park M; Gratton JP; Côté JF
    Proc Natl Acad Sci U S A; 2021 Jul; 118(29):. PubMed ID: 34266948
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic aspects of the Axl/Gas6 molecular system.
    Di Stasi R; De Rosa L; D'Andrea LD
    Drug Discov Today; 2020 Dec; 25(12):2130-2148. PubMed ID: 33002607
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MERTK Mediates Intrinsic and Adaptive Resistance to AXL-targeting Agents.
    McDaniel NK; Cummings CT; Iida M; Hülse J; Pearson HE; Vasileiadi E; Parker RE; Orbuch RA; Ondracek OJ; Welke NB; Kang GH; Davies KD; Wang X; Frye SV; Earp HS; Harari PM; Kimple RJ; DeRyckere D; Graham DK; Wheeler DL
    Mol Cancer Ther; 2018 Nov; 17(11):2297-2308. PubMed ID: 30093568
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.